about
Aberrant DNA hypermethylation of the ITIH5 tumor suppressor gene in acute myeloid leukemia.Second Line Chemotherapy for Advanced and Metastatic Urothelial Carcinoma: Vinflunine and Beyond-A Comprehensive Review of the Current Literature.Pharmacotherapeutic treatment of germ cell tumors: standard of care and recent developments.Cabazitaxel overcomes cisplatin resistance in germ cell tumour cells.Investigational targeted therapies for the treatment of testicular germ cell tumors.Platinum-refractory germ cell tumors: an update on current treatment options and developments.Impact of primary metastatic bone disease in germ cell tumors: results of an International Global Germ Cell Tumor Collaborative Group G3 Registry Study.Symptom burden in long-term germ cell tumor survivors.First salvage treatment in patients with advanced germ cell cancer after cisplatin-based chemotherapy: analysis of a registry of the German Testicular Cancer Study Group (GTCSG).Specific Characteristics of Patients with Advanced Genitourinary Cancer Receiving Specialized Inpatient Palliative Care.Anxiety and depression in long-term testicular germ cell tumor survivors.First salvage treatment of germ cell tumor patients with bone metastases: retrospective analysis of a large international database.Therapeutic approaches for refractory germ cell cancer.Retinal toxicity after cisplatin-based chemotherapy in patients with germ cell cancer.BCL2-overexpressing prostate cancer cells rely on PARP1-dependent end-joining and are sensitive to combined PARP inhibitor and radiation therapy.Corrigendum re: "Serum Levels of MicroRNA miR-371a-3p: A Sensitive and Specific New Biomarker for Germ Cell Tumours" [Eur Urol 2017;71:213-20].Loss of PTEN-assisted G2/M checkpoint impedes homologous recombination repair and enhances radio-curability and PARP inhibitor treatment response in prostate cancer.Questioning the Value of Fluorodeoxyglucose Positron Emission Tomography for Residual Lesions After Chemotherapy for Metastatic Seminoma: Results of an International Global Germ Cell Cancer Group RegistryEverolimus in patients with multiply relapsed or cisplatin refractory germ cell tumors: results of a phase II, single-arm, open-label multicenter trial (RADIT) of the German Testicular Cancer Study Group[Positron emission tomography in germ cell tumors in men : Possibilities and limitations]Palliative treatment of germ cell cancer5-Azacitidine Exerts Prolonged Pro-Apoptotic Effects and Overcomes Cisplatin-Resistance in Non-Seminomatous Germ Cell Tumor CellsBone metastases in germ cell tumor patientsNodal, pulmonary and pleural gliomatosis in a 42-year-old-male with non-seminomatous testicular germ cell cancerSerum Levels of MicroRNA miR-371a-3p: A Sensitive and Specific New Biomarker for Germ Cell TumoursThe Role of Salvage High-Dose Chemotherapy in Relapsed Male Germ Cell TumorsBiological basis and early clinical results of immunotherapy for cisplatin-resistant germ cell cancerTP53 and Prognosis in mCRPC Survival: Biology or Coincidence?ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-upAwareness of predatory journals and open access among medical oncologists: results of an online surveyExpression of miRNA-371a-3p in seminal plasma and ejaculate is associated with sperm concentrationTreatment of refractory germ-cell tumours with single-agent cabazitaxel: a German Testicular Cancer Study Group case seriesCurrent pharmacotherapy for testicular germ cell cancerEpigenetic treatment combinations to effectively target cisplatin-resistant germ cell tumors: past, present, and future considerations
P50
Q36001919-CF606155-9A4A-468C-A818-F5B38E02C894Q38593842-8A28419E-52AB-4757-BA08-29808969AFE4Q38656908-02C99888-53D3-4818-A0C2-316ADEA6D005Q38757753-5F8B1AFF-AF07-43D0-90DF-FB970C650CFCQ38861307-609688EF-A59A-468E-8E7A-9DB26885CC76Q38906007-2F096171-C49C-4C5F-A790-F5A99A865C8BQ39086345-F21A2D71-4FA3-4680-8D8F-1C9579EFB73CQ41118556-662B7543-E2F4-431F-8F53-CD5E83EAFCA0Q46946815-4B283740-02A7-4A74-8EE2-3AA093371FD8Q47568327-EBE2EF15-F182-4F02-9131-21C707F8F814Q47636211-6421FBB1-A5DD-4036-8585-7D33FCF3941AQ48456639-BA27649A-66D8-4C4D-92D0-ACFE14B7FD95Q52667403-4F464D14-1A5E-461C-8867-5394B7392AAFQ52893218-2B9F69FF-6919-4C91-844B-28C724D26D6DQ53436855-5FEC82FD-7B97-4BA1-A713-8CFE85E12E03Q54490288-7933C806-FFDA-4DB2-AF66-5258C5F59372Q55371418-8521F413-E2EE-49ED-B2B0-59AA79AF4B73Q57028102-FA7CF4A6-58A8-4C57-9BC7-0209172F983EQ57837577-803A6586-6715-4D77-9B18-332E3096A394Q58107877-63B76DCC-045E-406F-A0AA-06DDDD0E6056Q58579202-67FEF1E2-AA41-49A7-AD71-1CFF5967C3BDQ60939710-A425B50E-F82E-4E81-846B-D89CB64D94DBQ83476876-5F228B36-CBF9-4E1B-9A86-C14FF09EA3A6Q87130707-9D914E9D-4BAB-481D-8D4D-29B57DCA15EAQ88069560-324D5D77-ED22-4FF9-8F1B-6B28EBAF038DQ88906763-4EDB0694-D120-4134-98D2-0046A991CD01Q89347063-D5A2C8AA-C004-47C4-B322-9C82D606FA03Q90891949-15234D74-2005-42D7-8D7E-FD210794AF27Q90975825-B0DC6C42-C1C3-4069-AFDA-FFA53BFF9B35Q91710470-761DA9F1-870C-40B1-B6CB-884B3E650A17Q91918422-053112B4-EA21-42E6-B791-E287A3F64179Q91985216-E7978725-7D36-4AD4-ADF9-3EFF531C45D7Q92228812-99AE5C2E-71A6-4BBB-8F57-46D97F6A0CACQ92695854-A8A98B91-58C0-4315-BB11-2F5B2214E6D2
P50
description
researcher ORCID ID = 0000-0001-5578-3418
@en
wetenschapper
@nl
name
Christoph Oing
@ast
Christoph Oing
@en
Christoph Oing
@es
Christoph Oing
@nl
type
label
Christoph Oing
@ast
Christoph Oing
@en
Christoph Oing
@es
Christoph Oing
@nl
prefLabel
Christoph Oing
@ast
Christoph Oing
@en
Christoph Oing
@es
Christoph Oing
@nl
P214
P106
P1153
54924572100
P214
P31
P496
0000-0001-5578-3418
P735
P7859
viaf-296759359